National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, No. 35 Keyan Road, Zhunan Town, Miaoli County 350, Taiwan.
Expert Rev Vaccines. 2015 Mar;14(3):383-94. doi: 10.1586/14760584.2015.966696. Epub 2014 Dec 2.
The goal of therapeutic HPV vaccines is the induction of cytotoxic T lymphocyte immunity against HPV-associated cancers. Recombinant proteins and synthetic peptides have high safety profiles but low immunogenicity, which limits their efficacy when used in a vaccine. Self-adjuvanting lipid moieties have been conjugated to synthetic peptides or expressed as lipoproteins to enhance the immunogenicity of vaccine candidates. Mono-, di- and tri-palmitoylated peptides have been demonstrated to activate dendritic cells and induce robust cellular immunity against infectious diseases and cancer. Recently, a platform technology using the high-yield production of recombinant lipoproteins with Toll-like receptor 2 agonist activity was established for the development of novel subunit vaccines. This technology represents a novel strategy for the development of therapeutic HPV vaccines. In this review, we describe recent progress in the design of therapeutic HPV vaccines using lipoimmunogens.
治疗性 HPV 疫苗的目标是诱导针对 HPV 相关癌症的细胞毒性 T 淋巴细胞免疫。重组蛋白和合成肽具有较高的安全性，但免疫原性较低，这限制了它们在疫苗中的功效。自佐剂脂质部分已与合成肽缀合或表达为脂蛋白，以增强候选疫苗的免疫原性。单、二和三棕榈酰化肽已被证明可激活树突状细胞，并诱导针对传染病和癌症的强大细胞免疫。最近，建立了一种使用具有 Toll 样受体 2 激动剂活性的重组脂蛋白高产的平台技术，用于开发新型亚单位疫苗。该技术代表了治疗性 HPV 疫苗开发的一种新策略。在这篇综述中，我们描述了使用脂质免疫原设计治疗性 HPV 疫苗的最新进展。
